Displaying 61 - 80 of 108
Federal Trade Commission Closes Investigation of Roche Holding AG’s Proposed Acquisition of Spark Therapeutics, Inc.
FTC Requires Bristol-Myers Squibb Company and Celgene Corporation to Divest Psoriasis Drug Otezla as a Condition of Acquisition
Pharmaceutical Agreement Filing Procedures Updated
FTC Staff Issues FY 2016 Report on Branded Drug Firms’ Patent Settlements with Generic Competitors
FTC Staff Comment to the FDA Department of Health and Human Services on Its Updated Guidance for Industry on the “Nonproprietary Naming of Biological Products”
FTC Submits Comment on FDA Guidance Regarding Nonproprietary Naming of Biological Products
FTC Submits Comment on FDA Guidance Aimed at Deterring Abuse of Citizen Petition Process
Federal Trade Commission Comment On the Food and Drug Administration’s Revised Draft Guidance For Industry, Entitled “Citizen Petitions and Petitions For Stay of Action Subject To Section 505(q) of the Federal Food, Drug, and Cosmetic Act.”
FTC Submits Statement to HHS on Its Blueprint to Lower Drug Prices
FTC Approves Final Order Imposing Conditions on Merger of Generic Drug Marketers Amneal Pharmaceuticals LLC and Impax Laboratories Inc.
Amneal Holdings and Impax Laboratories, In the Matter of
FTC Requires Generic Drug Marketers Amneal Pharmaceuticals LLC and Impax Laboratories Inc. to Divest Rights to 10 Generic Medications as Condition of Merger
FTC Staff Issues FY 2015 Report on Branded Drug Firms’ Patent Settlements with Generic Competitors
Baxter International Inc., Claris Lifesciences Limited, and Arjun Handa, In the Matter of
Baxter International Inc. and Claris Lifesciences Limited have agreed to divest two types of pharmaceutical products to settle charges that Baxter’s proposed $625 million acquisition of Claris’ injectable drugs business would (1) reduce current competition in the United States for the antifungal agent fluconazole in saline intravenous bags, which is used to treat fungal and yeast infections, and (2)reduce future competition in the U.S. market for intravenous milrinone, which dilates the blood vessels, lowers blood pressure and allows blood to flow more easily through the cardiovascular system. Under the FTC order, the parties will divest all of Claris’s rights to fluconazole in saline intravenous bags and milrinone in dextrose intravenous bags to New Jersey-based pharmaceutical company Renaissance Lakewood LLC. The order requires Baxter to supply Renaissance with fluconazole in saline intravenous bags and milrinone in dextrose intravenous bags for up to five years while transferring the manufacturing technology to Renaissance or its contract manufacturing designee. Baxter is also required to assist Renaissance in establishing its manufacturing capabilities and securing the necessary FDA approvals.
Displaying 61 - 80 of 108